GlassScriptPhysician profile
Manuel Ferreira
NPI 1770803454
$2,606.65
in general payments reported to CMS, 2019-2025
26 companies · $549 in 2025
The $549 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $247 · 2021: $367 · 2022: $99.46 · 2023: $503 · 2024: $441 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.37 | 2019-2025 | |
| Astellas Pharma US INC | $403.04 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $269.10 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $255.24 | 2021 | |
| Mayne Pharma Commercial LLC | $183.51 | 2022-2025 | |
| Sage Therapeutics, LLC | $135.12 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $104.84 | 2019-2020 | |
| Evofem Biosciences, INC. | $101.27 | 2021-2025 | Solosec, Phexx, Phexxi |
| Coopersurgical, INC. | $90.99 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $79.15 | 2019-2025 | Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $68.05 | 2019-2023 | |
| Duchesnay USA Incorporated | $57.53 | 2019-2023 | Osphena, Bonjesta |
| Amag Pharmaceuticals, INC. | $48.07 | 2019-2020 | |
| Pfizer INC. | $44.60 | 2022-2023 | |
| Organon LLC | $43.17 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $37.20 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Allergan, INC. | $35.88 | 2019-2020 | |
| Exeltis, USA INC. | $34.52 | 2021-2023 | Slynd |
| Lupin INC. | $34.31 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $32.74 | 2019-2020 | |
| Agile Therapeutics, INC. | $24.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.96 | 2025 | Qelbree |
| Baxter Healthcare | $14.00 | 2019 | |
| Therapeuticsmd, INC. | $13.80 | 2020 | |
| Millicent US INC | $13.68 | 2019 | |
| Mission Pharmacal Company | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Ferreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.